

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000713 A1(51) International Patent Classification⁷: C07H 19/10,
19/20, A61K 31/70, A61P 31/14

[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY (GB).

(21) International Application Number: PCT/GB02/02269

(74) Agent: CRAWLEY, Karen; GlaxoSmithKline, Corporate Intellectual Property, 980 Great West Road (CN925.1), Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 15 May 2002 (15.05.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:



0115222.2 21 June 2001 (21.06.2001) GB
0200832.4 15 January 2002 (15.01.2002) GB(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.(71) Applicant (*for all designated States except US*): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB06 0NN (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): HOWES, Peter, David [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY (GB). SLATER, Martin, John

[Continued on next page]


(54) Title: NUCLEOSIDE COMPOUNDS IN HCV




(a)



(b)



(c)



(d)

(57) Abstract: Protide compounds of formula (I) wherein X represents H, F, N₃, NH₂, -CN, or -OMe; X¹ represents O or NR⁷; X² represents O, NH, NR⁶ or S, or when X³ is O then X² is absent; X³ is absent, or when X¹ is O then X³ represents O; R¹ represents hydrogen; optionally substituted C₁₋₆alkyl; optionally substituted aryl; or optionally substituted heteroaryl; R² represents hydroxy, OCOR⁶, or OCO₂R⁶; R³ represents H, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; R⁴ and R⁵ are independently selected from hydrogen, optionally substituted C₁₋₆alkyl, optionally substituted aryl, or optionally substituted aralkyl; R⁶ represents optionally substituted C₁₋₆alkyl or optionally substituted aryl; R⁷ represents H, optionally substituted C₁₋₆alkyl, or optionally substituted aryl, wherein when R⁴ and R⁷ are each alkyl they may be linked to form a 5- or 6-membered ring; B represents (a), (b), (c), or (d) wherein Z represents O or S; R⁸ represents H, halo, C₂₋₄alkynyl, trifluoromethyl, C₁₋₃alkoxy, hydroxy, methylthio, amino, nitro, or C₁₋₃alkyl wherein the C₁₋₃alkyl may be optionally substituted by hydroxy, halo, amino, or OR¹⁰ wherein R¹⁰ represents C₁₋₆alkyl optionally substituted by aryl which may itself be optionally substituted; and R⁹ represents H, halo, hydroxy, OR⁶, SR⁶ or NR³R³; are useful in the treatment of viral infection, particularly HCV infection.

WO 03/000713 A1

20717
#55



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NUCLEOSIDE COMPOUNDS IN HCV

FIELD OF THE INVENTION

5 The present invention relates to protide derivatives of therapeutically active nucleoside derivatives, processes for their manufacture, pharmaceutical formulations comprising them and their use in therapy, particularly for the treatment or prophylaxis of certain viral infections. In particular, we have found a group of compounds that are useful in treating viral infections, especially hepatitis C virus (HCV) infection.

BACKGROUND OF THE INVENTION

10 In the US, an estimated 4.5 million Americans are chronically infected with HCV. Although only 30% of acute infections are symptomatic, greater than 85% of infected individuals develop chronic, persistent infection. Treatment costs for HCV infection have been estimated at \$5.46 billion for the US in 1997. Worldwide over 200 million people are estimated to be infected chronically. HCV infection is responsible for 40-60% of all chronic liver disease and 30% of all liver transplants. Chronic HCV infection accounts for 30% of all cirrhosis, end-stage liver disease, and liver cancer in the U.S. The CDC estimates that the number of deaths due to HCV will minimally increase to 38,000/year by the year 2010.

25 Due to the high degree of variability in the viral surface antigens, existence of multiple viral genotypes, and demonstrated specificity of immunity, the development of a successful vaccine in the near future is unlikely. Alpha-interferon (alone or in combination with ribavirin) has been widely used since its approval for treatment of chronic HCV infection. However, adverse side effects are commonly associated with this treatment: flu-like symptoms, leukopenia, thrombocytopenia, depression from interferon, as well as anemia induced by ribavirin (Lindsay, K.L. (1997) Hepatology 26 (suppl 1):71S-77S). This therapy remains less effective against infections caused by HCV genotype 1 (which constitutes ~75% of all HCV infections in the developed markets) compared to infections caused by the other 5 major HCV genotypes. Unfortunately, only ~50-80% of the patients respond to this treatment (measured by a reduction in serum HCV RNA levels and normalization of liver enzymes) and, of those treated, 50-70% relapse within 6 months of cessation of treatment. Recently, with the introduction of pegylated interferon, both initial and sustained response rates have improved substantially, and combination treatment of Peg-IFN with ribavirin constitutes the gold standard for therapy. However, the side effects associated with combination therapy and the impaired response in patients with genotype 1 present opportunities for improvement in the management of this disease.

40 First identified by molecular cloning in 1989 (Choo, Q-L et al (1989) Science 244:359-362), hepatitis C virus (HCV) is now widely accepted as the most common causative agent of post-transfusion non A, non-B hepatitis (NANBH) (Kuo, G et al (1989) Science

244:362-364). Due to its genome structure and sequence homology, this virus was assigned as a new genus in the *Flaviviridae* family. Like the other members of the *Flaviviridae*, such as flaviviruses (e.g. yellow fever virus and Dengue virus types 1-4) and pestiviruses (e.g. bovine viral diarrhea virus, border disease virus, and classic swine fever virus) (Choo, Q-L et al (1989) Science 244:359-3; Miller, R.H. and R.H. Purcell (1990) Proc. Natl. Acad. Sci. USA 87:2057-2061), HCV is an enveloped virus containing a single strand RNA molecule of positive polarity. The HCV genome is approximately 9.6 kilobases (kb) with a long, highly conserved, noncapped 5' nontranslated region (NTR) of approximately 340 bases which functions as an internal ribosome entry site (IRES) (Wang CY et al 'An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region' [Article] Rna-A Publication of the Rna Society. 1(5):526-537, 1995 Jul.). This element is followed by a region which encodes a single long open reading frame (ORF) encoding a polypeptide of ~3000 amino acids comprising both the structural and nonstructural viral proteins.

Upon entry into the cytoplasm of the cell, this RNA is directly translated into a polypeptide of ~3000 amino acids comprising both the structural and nonstructural viral proteins. This large polypeptide is subsequently processed into the individual structural and nonstructural proteins by a combination of host and virally-encoded proteinases (Rice, C.M. (1996) in B.N. Fields, D.M.Knipe and P.M. Howley (eds) Virology 2nd Edition, p931-960; Raven Press, N.Y.). Following the termination codon at the end of the long ORF, there is a 3' NTR which roughly consists of three regions: an ~ 40 base region which is poorly conserved among various genotypes, a variable length poly(U)/polypyrimidine tract, and a highly conserved 98 base element also called the "3' X-tail" (Kolykhalov, A. et al (1996) J. Virology 70:3363-3371; Tanaka, T. et al (1995) Biochem Biophys. Res. Commun. 215:744-749; Tanaka, T. et al (1996) J. Virology 70:3307-3312; Yamada, N. et al (1996) Virology 223:255-261). The 3' NTR is predicted to form a stable secondary structure which is essential for HCV growth in chimps and is believed to function in the initiation and regulation of viral RNA replication.

The NS5B protein (591 amino acids, 65 kDa) of HCV (Behrens, S.E. et al (1996) EMBO J. 15:12-22), encodes an RNA-dependent RNA polymerase (RdRp) activity and contains canonical motifs present in other RNA viral polymerases. The NS5B protein is fairly well conserved both intra-typically (~95-98% amino acid (aa) identity across 1b isolates) and inter-typically (~85% aa identity between genotype 1a and 1b isolates). The essentiality of the HCV NS5B RdRp activity for the generation of infectious progeny virions has been formally proven in chimpanzees (A. A. Kolykhalov et al. (2000) Journal of Virology, 74(4), p.2046-2051). Thus, inhibition of NS5B RdRp activity (inhibition of RNA replication) is predicted to cure HCV infection.


Based on the foregoing, there exists a significant need to identify synthetic or biological compounds for their ability to inhibit HCV.

Some nucleoside derivatives, for example AZT, 3TC and abacavir, which are useful in the treatment of HIV, are known to undergo metabolism when inside cells to form phosphate derivatives. In particular, triphosphate derivatives have been demonstrated to be active against some viral targets. However, triphosphate compounds are not easily transported across cell membranes so that they are often not suitable for direct administration to patients.

It has now been discovered that derivatives of certain nucleoside compounds have potential for the treatment or prophylaxis of viral infections, for example hepatitis C virus, due to their ability to inhibit HCV polymerase or their ability to gain entry to cells where they are converted to compounds which inhibit HCV polymerase.

DETAILED DESCRIPTION OF INVENTION

According to one aspect of the present invention, we provide compounds of formula (I)



wherein X represents H, F, N₃, NH₂, -CN, or -OMe;

X¹ represents O or NR⁷;

X² represents O, NH, NR⁶ or S, or when X³ is O then X² is absent;

X³ is absent, or when X¹ is O then X³ represents O;

R¹ represents hydrogen; optionally substituted C₁₋₆alkyl; optionally substituted aryl; or optionally substituted heteroaryl;

R² represents hydroxy, OCOR⁶, or OCO₂R⁶;





R³ represents H, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;

R^4 and R^5 are independently selected from hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted aryl, or optionally substituted aralkyl;

R^6 represents optionally substituted C_{1-6} alkyl or optionally substituted aryl;

R^7 represents H, optionally substituted C_{1-6} alkyl, or optionally substituted aryl, wherein when R^4 and R^7 are each alkyl they may be linked to form a 5- or 6- membered ring;

B represents (a), (b), (c), or (d)



wherein Z represents O or S;


R^8 represents H, halo, C_{2-4} alkynyl, trifluoromethyl, C_{1-3} alkoxy, hydroxy, methylthio, amino, nitro, or C_{1-3} alkyl wherein the C_{1-3} alkyl may be optionally substituted by hydroxy, halo, amino, or OR^{10} wherein R^{10} represents C_{1-6} alkyl optionally substituted by aryl which may itself be optionally substituted; and

R^9 represents H, halo, hydroxy, OR^6 , SR^6 or NR^3R^3 ;

and salts and solvates thereof (hereinafter "compounds of the invention").

According to a further aspect of the present invention, we provide compounds of formula (Ia)

5



wherein X represents H, F, N₃, NH₂, -CN, or -OMe;

5 X¹ represents O or NR⁷;

X² represents O, NH, NR⁶ or S, or when X³ is O then X² is absent;

X³ is absent, or when X¹ is O then X³ represents O;

10

R¹ represents hydrogen; optionally substituted aryl; or optionally substituted heteroaryl;

R² represents hydroxy, OCOR⁶, or OCO₂R⁶;

15

R³ represents H, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;

R⁴ and R⁵ are independently selected from hydrogen, optionally substituted C₁₋₆alkyl, optionally substituted aryl, or optionally substituted aralkyl;


20

R⁶ represents optionally substituted C₁₋₆alkyl or optionally substituted aryl;


R⁷ represents H, optionally substituted C₁₋₆alkyl, or optionally substituted aryl, wherein when R⁴ and R⁷ are each alkyl they may be linked to form a 5- or 6- membered ring;

25


B represents (a), (b), (c), or (d)




(a)



(b)



(c)



(d)

wherein Z represents O or S;

5 R^8 represents halo, C_{2-4} alkynyl, trifluoromethyl, C_{1-3} alkoxy, hydroxy, methylthio, amino, nitro, or C_{1-3} alkyl wherein the C_{1-3} alkyl may be optionally substituted by hydroxy, halo, amino, or OR^{10} wherein R^{10} represents C_{1-6} alkyl optionally substituted by aryl which may itself be optionally substituted; and

10 R^9 represents H, halo, hydroxy, OR^6 , SR^6 or NR^3R^3 ;

and salts and solvates thereof.

15 Compounds of formula (I) and (Ia) contain more than one asymmetric carbon atom, and the invention includes all diastereoisomers of compounds of formula (I) and (Ia) and mixtures thereof.

20 The present invention also includes the physiologically acceptable salts of the compounds of formula (I) and (Ia). Suitable physiologically acceptable salts of the compounds of formula (I) and (Ia) include acid salts, for example sodium, potassium, calcium, magnesium and tetraalkylammonium and the like, or mono- or di- basic salts with the appropriate acid for example organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids and the like.

25 The present invention also relates to solvates of the compounds of Formula (I) and (Ia), for example hydrates.

30 The present invention relates to protide compounds (prodrugs of nucleoside monophosphates), as defined by Formula (I) and (Ia). When used herein, the term "protide" refers to stabilized phosphate derivatives, for example such derivatives as

described in Koszalka, G.W., Daluge, S.M., Boyd, F.L., Annual Rep Med Chem 1998, 33, 163-171 and the references cited therein (the contents of which are incorporated herein by reference thereto). Examples of protides include, but are not restricted to, phosphoramidates of the compounds of Formula (I) and (Ia).

5

When used herein, the term "phosphoramidate" refers to a group attached to the phosphorus atom of a mono-phosphate derivative (nucleotide) of Formula (I) and (Ia), via a nitrogen atom.

10

When used herein, the term "alkyl" includes a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. The term "Me" means methyl. When used herein, the term "alkynyl" includes branched as well as straight chain alkynyl, for example ethynyl and propynyl.

15

When used herein, the term "aryl" represents an optionally substituted 5 to 14 membered, preferably 6 to 10 membered, monocyclic or bicyclic aromatic ring system, for example phenyl.

20

When used herein, the term "heteroaryl" represents an optionally substituted 5 to 14 membered, preferably 6 to 10 membered, monocyclic or bicyclic aromatic ring system, comprising one to four heteroatoms selected from O, N and S.

25

When used herein, the term "heterocyclyl" represents an optionally substituted, 5 or 6 membered, saturated cyclic hydrocarbon group containing one to four heteroatoms selected from N, optionally substituted by hydrogen, C_{1-6} alkyl, $C(O)R^3$, SO_2R^3 , aryl or heteroaryl; O; and S, optionally substituted by one or two oxygen atoms.

When used herein, the term "halo" represents chloro, bromo, fluoro, or iodo.

30

Unless otherwise stated, when used herein, the term "optionally substituted" includes aryl (e.g. phenyl), C_{1-6} alkyl (e.g. methyl, ethyl), nitro, oxo, OR, CO_2R , SO_2R , NRR, CONRR, SONRR, $CH_2N(Me)_2$, and halo. R represents H, C_{1-6} alkyl, or aryl.

35

Preferably, X represents H;

Preferably X^1 represents NR^7 where R^7 represents H;

Preferably X^2 represents O;

40

Preferably X^3 is absent;

Preferably R^1 represents optionally substituted aryl or optionally substituted heteroaryl;

more preferably R^1 represents optionally substituted aryl; most preferably R^1 represents phenyl or 4-*tert*-butylphenyl;

Preferably R^2 represents hydroxy;

Preferably R^3 represents optionally substituted C_{1-6} alkyl; more preferably R^3 represents methyl or benzyl;

Preferably R^4 represents H;

Preferably R^5 represents C_{1-6} alkyl; more preferably R^5 represents methyl;

Preferably B represents (b) or (c);

Preferably R^8 represents H;

Preferably R^9 represents H, hydroxy or NR^3R^3 where R^3 represents H;

Preferably Z represents O;

Preferably the stereochemistry of the sugar is beta-D-ribofuranose.

Preferred compounds of Formula (I) include :


3'-deoxyguanosine 5'-[4-(1,1-dimethylethyl)phenyl N-[(1S)-1-methyl-2-oxo-2-(phenylmethoxy)ethyl]phosphoramidate];

3'-deoxycytidine 5'-[phenyl N-[(1S)-2-methoxy-1-methyl-2-oxoethyl] phosphoramidate];
and

3'-deoxycytidine 5'-[phenyl N-[(1S)-1-methyl-2-oxo-2-(phenylmethoxy)ethyl] phosphoramidate];

and salts and solvates thereof.

Processes



Compounds of Formula (I) and (Ia) may be prepared from compounds of Formula (II) using a reagent $R^1O[X^1C(R^4)(R^5)X^3C(O)X^2(R^3)]P(O)Cl$ in a suitable solvent such as tetrahydrofuran, DMF, or acetonitrile with a suitable base such as pyridine, N-methyl

imidazole, or *tert*-butyl magnesium chloride. Where R^2 represents hydroxy, and B represents (b), the preferred solvent is a combination of tetrahydrofuran and pyridine, and the preferred base is *tert*-butyl magnesium chloride used in excess (greater than 2 equivalents).

Compounds of formula $R^1O[X^1C(R^4)(R^5)X^3C(O)X^2(R^3)]P(O)Cl$ may be prepared from compounds of formula $P(O)Cl_3$ by standard methods known in the art (see for example Koszalka, G.W., Daluge, S.M., Boyd, F.L., Annual Rep Med Chem 1998, 33, 163-171 and the references cited therein).

Compounds of formula (II) may be prepared by methods analogous to those known in the art, for example Collect. Czech. Chem. Commun. (1973) 38, 1173-78; Tetrahedron (1998) 54, 13529-46; J. Med. Chem. (1991) 34, 2195; J. Chem. Soc. Chem Commun. (1989) 14, 955-57; G.Gosselin et al, Nucleosides and Nucleotides (1995) 14, 611-617; A. Kumar et al, Nucleosides and Nucleotides (1994) 13, 1049-1057; and T-S Lin et al, J. Med. Chem. (1991) 34, 693-701.

Compounds of Formula (I) and (Ia) in which R^2 is hydroxy may also be prepared from compounds of Formula (II) by protecting the R^2 hydroxy group with a suitable protecting agent, for example as an ether (using benzyl ether or silyl ether), or as an ester, then reacting with a reagent $R^1O[X^1C(R^4)(R^5)X^3C(O)X^2(R^3)]P(O)Cl$ in a suitable solvent such as tetrahydrofuran, DMF, or acetonitrile with a suitable base such as pyridine, N-methyl imidazole, or *tert*-butyl magnesium chloride, and finally deprotecting the hydroxy group. Suitable protecting groups may be found, but are not limited to, those described in TW Greene and PGM Wuts 'Protective Groups in Organic Synthesis', 3rd edition (1999), J Wiley and Sons.

Assay

The potential for compounds of the invention to inhibit NSSB wildtype HCV polymerase activity may be demonstrated, for example, using the following cell based assay :

Replicon ELISA

Cells

The 5-15 subline of Huh-7 cells (Lohmann, V., Korner, F., Koch, J.-O., Herian, U., Theilmann, L. & Bartenschlager, R., 1999, *Science*, 285, pp110-113) were used for these assays. These are human hepatocellular carcinoma cells stably transfected with an HCV replicon comprising the majority of the HCV 1b genome with the addition of a selectable marker gene, but lacking the genes encoding for all structural proteins and non-structural protein (NS) 2. The replicon RNA is self-replicating and fully functional viral proteins are translated from it. A quantifiable and specific reduction of expressed protein in the presence of a drug can be used as a measure of replicon inhibition.

Compounds

Stock solutions of compound samples were formulated to 40mM in DMSO.

Method

Culture step: 100µl volumes of assay medium (Dulbecco's Minimal Essential Medium (DMEM) with 4500mg/L glucose and supplemented with 10% foetal bovine serum, 100iu/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine and 1% non-essential amino acids solution) were added to each well of a 96-well tissue culture plate. The 40mM stock solutions of compound were further diluted in assay medium to twice the highest final concentration required, and 100µl aliquots were transferred into two wells in the top row of the plate. Serial doubling dilutions were then made down the plate leaving the bottom two rows compound free. A 100µl volume of Huh-7 5-15 cell suspension of 2×10^5 cells /ml in assay medium was added to all wells. The plates were incubated at 37°C in a 5% CO₂ atmosphere for 72 hours.

ELISA step: Growth medium was removed from the plate and the cell monolayers were washed gently once with phosphate buffered saline (PBS) prior to fixing with a 1:1 mix of acetone:methanol for 5 minutes. The plate was washed again with PBS, blotted dry and 100µl of ELISA diluent (PBS + 0.05% Tween 20 + 2% skimmed milk powder) was added to each well. The plate was incubated at 37°C for 30 minutes and the diluent removed. Each well, except one row of the compound free wells, then received 50µl of murine monoclonal antibody, diluted to 1µg/ml, raised to a non-structural protein, more specifically NS4a. The control row received 50µl/well of diluent alone. The plate was incubated for 2 hours, the primary antibody was removed and the cell sheets washed thoroughly with PBS + 0.05% Tween 20. Rabbit anti-mouse, polyclonal antibody conjugated to horseradish peroxidase was diluted 1/1000 and 50µl was added to all wells. Following incubation for one further hour, the secondary antibody was removed and the plate was washed thoroughly in PBS/Tween. The plate was blotted dry and 50µl of orthophenylene diamine / peroxide substrate in urea buffer was added to all wells and colour development was allowed to proceed at room temperature. The reaction was stopped by the addition of 25µl per well of 2M sulphuric acid and the plates were read spectrophotometrically at 490nm.

The ELISA solutions were removed from the plates, and the cell sheets were washed with water, blotted dry and stained with 5% carbol fuchsin. After 30 minutes the stain was removed and the plates were washed with water and allowed to air dry.

Data analysis

The absorbance values from all compound-free wells that had received both primary and secondary antibodies were averaged to obtain a positive control value. The mean absorbance value from the compound-free wells that had not received the primary antibody was used to provide the negative (background) control value. The readings from the duplicate wells at each compound concentration were averaged and, after the subtraction of the mean background from all values, were expressed as a percentage of the positive control signal. Grafit software was used to plot the curve of percentage inhibition against compound concentration and derive the 50% inhibitory concentration (IC₅₀) for the compound.

In-assay cytotoxicity was assessed by microscopic examination of the stained cell sheets, and expressed as the lowest compound concentration at which any cellular effect was visible.

5 Accordingly, the compounds of the invention are of potential therapeutic benefit in the treatment and prophylaxis of HCV.

10 Thus, there is provided as a further aspect of the present invention a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in human or veterinary medicine, particularly in the treatment or prophylaxis of viral infection, particularly HCV infection. Compounds of the present invention are also useful in the treatment and/or prophylaxis of viral infection by hepaciviruses, such as GBV-A, GBV-B, GBV-C and HCV, pestiviruses, such as BVDV, and flaviviruses such as West Nile Virus and Yellow Fever Virus.

15 It will be appreciated that references herein to treatment extend to prophylaxis as well as the treatment of established conditions. It will further be appreciated that references herein to treatment or prophylaxis of HCV infection includes treatment or prophylaxis of HCV-associated disease such as liver fibrosis, cirrhosis and hepatocellular carcinoma.

20 According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment and/or prophylaxis of viral infection, particularly HCV infection.

25 According to another aspect of the invention, there is provided a compound of formula (I) or a physiologically acceptable salt or solvate thereof use in treating and/or the prophylaxis of a viral infection, particularly HCV infection.

30 In a further or alternative aspect there is provided a method for the treatment of a human or animal subject with viral infection, particularly HCV infection, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.

35 The compounds according to the invention may be formulated for administration in any convenient way, and the invention therefore also includes within its scope pharmaceutical compositions for use in therapy, comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof in admixture with one or more physiologically acceptable diluents or carriers.

40 There is also provided according to the invention a process for preparation of such a pharmaceutical composition which comprises mixing the ingredients.

The compounds according to the invention may, for example, be formulated for oral, buccal, parenteral, topical or rectal administration.

5 Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium
10 lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl
15 cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl p-hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

25 The compounds may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

30 The compounds according to the invention may also be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative. The compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or
35 toxicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.

40 By topical administration as used herein, we include administration by insufflation and inhalation. Examples of various types of preparation for topical administration include

ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).

5 Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents. Such bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol. Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax.

10 Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.

15 Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.

20 Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,2-tetrafluoroethane, carbon dioxide or other suitable gas.

25 Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin, may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

30 The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example immune therapies (eg. interferon), therapeutic vaccines, antifibrotic agents, anti-inflammatory agents such as corticosteroids or NSAIDs, bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline), mucolytic agents, anti-muscarinics, anti-leukotrienes, inhibitors of cell adhesion (e.g. ICAM antagonists), anti-oxidants (eg N-acetylcysteine), cytokine agonists, cytokine antagonists, lung surfactants and/or antimicrobial and anti-viral agents (eg ribavirin and amantidine). The compositions according to the invention may also be used in combination with gene replacement therapy.

40 The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutically active agent.

The combination referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof represent a further aspect of the invention.

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.

The compound of the invention may conveniently be administered in amounts of, for example, 0.01 to 100mg/kg body weight, suitably 0.05 to 25mg/kg body weight orally, one or more times a day. The precise dose will of course depend on the age and condition of the patient, the particular route of administration chosen, and is entirely within the discretion of the administering physician.

The compounds of the invention have useful duration of action.

The following non-limiting Examples illustrate the present invention.

Examples

Intermediate 1

4-tert-Butylphenyl phosphodichloridate

A solution containing 4-tert-butylphenol (15.0g, 0.1 Mol) and triethylamine (13.95 mL) in ether (200 mL) was added dropwise with stirring at 0°C over 2h to a solution of phosphoryl chloride (11.1 mL) in ether (100 mL). The cooling bath was removed and the mixture was stirred for a further 18h. The mixture was filtered and volatiles were removed from the filtrate to give a pale yellow oil which was distilled to give the title compound as a colourless oil (18.72g).

NMR: (CDCl₃) δ 7.43 (d, J=8.5Hz, 2H); 7.20 (dd, J=8.5, 2.25 Hz, 2H); 1.32 (s, 9H).

Intermediate 2

L-Alanine, N-(chlorophenoxyphosphinyl) methyl ester

A suspension of L-alanine methyl ester hydrochloride (1.00g, 7.2 mMol) in dichloromethane (10 mL) was treated with phenyl phosphorodichloridate (1.07g, 5.1 mMole). The mixture was stirred under nitrogen and cooled to -78°C. Di-isopropylethylamine (2.5 mL) was added in portions over 30 min. The cooling bath was removed and the mixture was stirred at room temperature overnight. Volatiles were removed *in vacuo*. The residue was extracted with ether (25 mL) and the extracts were concentrated to give the title compound as a colourless oil (1.25g), used with no further purification.

NMR: (CDCl₃) δ 7.1 – 7.4 (m, 5H); 4.0 – 4.3 (m, 1H); 3.71 + 3.72 (2x s, total 3H); 1.53 + 1.39 (2x m, 3H total).

Intermediate 3**L-Alanine, N-(chlorophenoxyphosphinyl) phenylmethyl ester**


The title compound was prepared as an oil according to the procedure described for Intermediate 2, using L-alanine benzyl ester hydrochloride and phenyl phosphorodichloridate.

NMR: (CDCl₃) δ 7.1 – 7.4 (m, 10H); 5.20 + 5.22 (2x s, 2H); 4.9 – 5.1 (m, 1H); 1.51 + 1.52 (2x d, 3H total).

Intermediate 4**L-Alanine, N-(chloro-4-tert-butylphenoxyphosphinyl) phenylmethyl ester**

The title compound was prepared as a colourless oil according to the procedure described for Intermediate 2, using L-alanine benzyl ester hydrochloride and Intermediate 1.

NMR: (CDCl₃) δ 7.32 – 7.40 (m, 7H); 7.15 (m, 2H); 5.21 (m, 2H); 4.18 – 4.36 (m, 2H); 1.52 (2, 3H); 1.30 (s, 9H).

Example 1**3'-Deoxyguanosine-5'-[4-(1,1-dimethylethyl)phenyl-N-[(1S)-1-methyl-2-oxo-2-(phenylmethoxy)ethyl]phosphoramidate]**


A suspension of 3'-deoxyguanosine (27 mg) in pyridine (1 mL) was stirred under nitrogen and treated with 1.0M tert-butyl magnesium chloride in tetrahydrofuran (220 μ L). The resulting solution was stirred at 20°C for 1h and then treated with a solution of Intermediate 4 (45 mg) in tetrahydrofuran (0.8 mL). The mixture was stirred for a further 18h and then evaporated to dryness. The residue was partitioned between water (10 mL) and ethyl acetate (25 mL). The organic phase was collected and dried (MgSO₄). Removal of solvent gave a colourless gum which was purified on silica gel preparative plates with 8:1 (v:v) dichloromethane:methanol affording the title compound as a solid.

Mass spec (electrospray) m/z calcd for (C₃₀H₃₇N₆O₈P+H)⁺ : 641.

Found: (M+H)⁺ = 641.

Example 2**3'-Deoxycytidine-5'-[phenyl-N-[(1S)-2-methoxy-1-methyl-2-oxoethyl]phosphoramidate]**

16




A suspension of 3'-deoxycytidine (25 mg) in pyridine (1 mL) was stirred under nitrogen at -10°C and treated with 1.0M tert-butyl magnesium chloride in tetrahydrofuran (260µL). The resulting mixture was stirred for a further 20 min and then treated with a solution of Intermediate 2 (37 mg) in pyridine (0.6 mL). The mixture was stirred at 0°C for 4h and then stored at 0°C for 18h. Solvent was removed under reduced pressure. The residue was purified on silica gel preparative plates with 8:1 (v:v) dichloromethane:methanol affording the title compound as a solid.

Mass spec (electrospray) m/z calcd for (C₁₉H₂₅N₄O₈P+H)⁺: 469.

Found: (M+H)⁺ = 469.

Example 3

3'-Deoxycytidine-5'-[phenyl-N-[(1S)-1-methyl-2-oxo-2-(phenylmethoxy)ethyl]phosphoramidate]



To a suspension of 3'-deoxycytidine (25mg, 0.11mMol) in dry pyridine (1ml) was added tert-butylmagnesium chloride (1.0M solution in THF, 352µl, 0.35mMol) giving an orange suspension which was stirred at ambient temperature under nitrogen for 1h. Intermediate 3 (0.14mMol, 47.8mg) in dry THF (1ml) was added and the reaction mixture was stirred for a further 3.5h. The reaction was then quenched with methanol (1ml) and the volatiles were evaporated in vacuo. The residue was partitioned between ethyl acetate and water and the organics were dried (MgSO₄), filtered and evaporated to give a white solid (29.5mg). The crude product was purified on silica gel preparative plates with 9:1 (v:v) dichloromethane:methanol affording the title compound as a white solid.

Mass spec (electrospray) m/z calcd for (C₂₅H₂₉N₄O₈P+H)⁺: 545.


Found: (M+H)⁺ = 545.

Biological Data

The compounds of Examples 1-3 were tested in the in vitro tests described earlier. All the compounds had an IC₅₀ value of <200µM in the HCV replicon assay.

CLAIMS

1. Compounds of formula (I)



wherein X represents H, F, N₃, NH₂, -CN, or -OMe;

X¹ represents O or NR⁷;

X² represents O, NH, NR⁶ or S, or when X³ is O then X² is absent;

X³ is absent, or when X¹ is O then X³ represents O;

R¹ represents hydrogen; optionally substituted C₁₋₆alkyl; optionally substituted aryl; or optionally substituted heteroaryl;

R² represents hydroxy, OCOR⁶, or OCO₂R⁶;





R³ represents H, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;

R⁴ and R⁵ are independently selected from hydrogen, optionally substituted C₁₋₆alkyl, optionally substituted aryl, or optionally substituted aralkyl;

R⁶ represents optionally substituted C₁₋₆alkyl or optionally substituted aryl;

R⁷ represents H, optionally substituted C₁₋₆alkyl, or optionally substituted aryl, wherein when R⁴ and R⁷ are each alkyl they may be linked to form a 5- or 6- membered ring;

B represents (a), (b), (c), or (d)




wherein Z represents O or S;

R^8 represents H, halo, C_{2-4} alkynyl, trifluoromethyl, C_{1-3} alkoxy, hydroxy, methylthio, amino, nitro, or C_{1-3} alkyl wherein the C_{1-3} alkyl may be optionally substituted by hydroxy, halo, amino, or OR^{10} wherein R^{10} represents C_{1-6} alkyl optionally substituted by aryl which may itself be optionally substituted; and

R^9 represents H, halo, hydroxy, OR^6 , SR^6 or NR^3R^3 ;

and salts and solvates thereof.

2. Compounds of formula (I) as claimed in claim 1, represented by formula (Ia)



wherein X represents H, F, N_3 , NH_2 , $-CN$, or $-OMe$;

X^1 represents O or NR^7 ;

X^2 represents O, NH , NR^6 or S, or when X^3 is O then X^2 is absent;

X^3 is absent, or when X^1 is O then X^3 represents O;

R^1 represents hydrogen; optionally substituted aryl; or optionally substituted heteroaryl;

R^2 represents hydroxy, $OCOR^6$, or OCO_2R^6 ;


R^3 represents H, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;

R^4 and R^5 are independently selected from hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted aryl, or optionally substituted aralkyl;

R^6 represents optionally substituted C_{1-6} alkyl or optionally substituted aryl;

R^7 represents H, optionally substituted C_{1-6} alkyl, or optionally substituted aryl, wherein when R^4 and R^7 are each alkyl they may be linked to form a 5- or 6- membered ring;

B represents (a), (b), (c), or (d)



wherein Z represents O or S;

R⁸ represents halo, C₂₋₄alkynyl, trifluoromethyl, C₁₋₃alkoxy, hydroxy, methylthio, amino, nitro, or C₁₋₃alkyl wherein the C₁₋₃alkyl may be optionally substituted by hydroxy, halo, amino, or OR¹⁰ wherein R¹⁰ represents C₁₋₆alkyl optionally substituted by aryl which may itself be optionally substituted; and

R⁹ represents H, halo, hydroxy, OR⁶, SR⁶ or NR³R³; and salts and solvates thereof.

3. A compound of formula (I), as claimed in claim 1, for use in medical therapy.


4. Use of a compound of formula (I), as claimed in claim 1, in the manufacture of a medicament for the treatment and/or prophylaxis of viral infection.

5. Use as claimed in claim 4 wherein the viral infection is HCV infection.

6. A method for the treatment of a human or animal subject with viral infection, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as claimed in claim 1.

7. A method as claimed in claim 6, wherein the viral infection is HCV infection.

8. A process for the preparation of a compound of Formula (I) as claimed in claim 1, comprising reaction of a compound of Formula (II)



wherein B, X and R² are as described in Formula (I), with a reagent R¹O[X¹C(R⁴)(R⁵)X³C(O)X²(R³)]P(O)Cl, wherein R¹, R³-R⁵ and X¹-X³ are as described in Formula (I), in a suitable solvent with a suitable base.

9. A pharmaceutical formulation comprising a compound of Formula (I) as claimed in claim 1 together with a pharmaceutically acceptable diluent or carrier therefor.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02269

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H19/10 C07H19/20 A61K31/70 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | WO 00 23455 A (GIRIJAVALLABHAN VIYYOOR M ; MCCORMICK JINPING (US); BENNETT FRANK () 27 April 2000 (2000-04-27) the whole document | 1,4,6,8, 9 |
| A | WO 96 29336 A (MEDICAL RES COUNCIL ; UNIV CARDIFF (GB); REGA FOUNDATION (BE); MCGU 26 September 1996 (1996-09-26) the whole document | 1,4,6,8, 9 |
| A | WO 99 49873 A (UNIV MINNESOTA ; GRIESGRABER GEORGE W (US); WAGNER CARSTON R (US)) 7 October 1999 (1999-10-07) see the whole document but especially page 12, lines 1-3, claim 1, and figs 1,3-5 -/-- | 1,4,6,8, 9 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

3 July 2002

Date of mailing of the international search report

16/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02269

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P,X | WO 01 90121 A (UNI DEGLI STUDI DI CAGLIARI ;LACOLLA PAULO (IT); NOVIRIO PHARMACEU) 29 November 2001 (2001-11-29) see the whole application, but especially claims 136-140 ----- | 1-9 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 02/02269

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 6 and 7 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02269

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 0023455 | A | 27-04-2000 | AU 1197500 A | 08-05-2000 |
| | | | AU 1197600 A | 08-05-2000 |
| | | | BR 9915546 A | 14-08-2001 |
| | | | CN 1330658 T | 09-01-2002 |
| | | | CZ 20011130 A3 | 15-08-2001 |
| | | | EP 1121369 A1 | 08-08-2001 |
| | | | EP 1121370 A1 | 08-08-2001 |
| | | | NO 20011789 A | 11-06-2001 |
| | | | PL 347268 A1 | 25-03-2002 |
| | | | SK 4742001 A3 | 06-11-2001 |
| | | | TR 200101085 T2 | 21-08-2001 |
| | | | WO 0023454 A1 | 27-04-2000 |
| | | | WO 0023455 A1 | 27-04-2000 |
| | | | US 6277830 B1 | 21-08-2001 |
| WO 9629336 | A | 26-09-1996 | AU 707196 B2 | 08-07-1999 |
| | | | AU 5009496 A | 08-10-1996 |
| | | | CA 2215190 A1 | 26-09-1996 |
| | | | EP 0820461 A1 | 28-01-1998 |
| | | | WO 9629336 A1 | 26-09-1996 |
| | | | JP 11506419 T | 08-06-1999 |
| | | | NZ 303711 A | 25-02-1999 |
| WO 9949873 | A | 07-10-1999 | AU 3363499 A | 18-10-1999 |
| | | | CA 2326535 A1 | 07-10-1999 |
| | | | WO 9949873 A1 | 07-10-1999 |
| WO 0190121 | A | 29-11-2001 | AU 7490601 A | 03-12-2001 |
| | | | WO 0190121 A2 | 29-11-2001 |

THIS PAGE BLANK (USPTO)